NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) disclosed that a preclinical study published on bioRxiv on November 25, 2025, found that focused ultrasound markedly increases the antitumor activity of its lead candidate, NEO100, across a range of primary and metastatic brain tumor models. The study, conducted in partnership with the University of Southern California, used an AI‑driven, 3‑D bioprinted organoid platform to screen more than 200 compounds for sonodynamic activity, with NEO100 emerging as the top candidate. The organoids included glioblastoma, medulloblastoma, meningioma, and breast‑ and lung‑to‑brain metastasis models, all of which showed enhanced tumor‑killing effects when combined with focused ultrasound parameters.
The findings expand NEO100’s therapeutic scope beyond its current intranasal delivery approach and support NeOnc’s strategy to develop a versatile, blood‑brain‑barrier‑penetrant platform. NEO100 is already in Phase II clinical trials and has received FDA Fast‑Track status, while a related candidate, NEO212, is also in Phase II. The preclinical data suggest that ultrasound could be incorporated into future clinical trials to amplify NEO100’s efficacy, potentially accelerating the path to regulatory approval and broader market access.
NeOnc’s financial profile remains modest: the company reported $0.06 million in revenue for the most recent twelve months and a net loss of $8.62 million, with a market capitalization of approximately $174.3 million as of December 1, 2025. The company maintains moderate debt levels and holds exclusive worldwide patent protection for NEO100 and related products through 2038. The preclinical breakthrough provides external validation of NEO100’s first‑in‑class, noninvasive sonodynamic therapeutic potential, a point highlighted by Executive Chairman and President Amir Heshmatpour, who said the study “provides strong external validation for NEO100’s potential as a first‑in‑class, noninvasive sonodynamic therapeutic.”
Because the study was posted on a preprint server, the results have not yet undergone peer review, and the company has not yet received regulatory approval for the ultrasound combination. Nonetheless, the data represent a significant milestone that could influence the company’s future clinical development strategy and investor perception of its pipeline strength.
The market has reacted positively to the announcement, with analysts noting the potential for a faster regulatory pathway and broader therapeutic indications. The breakthrough underscores NeOnc’s commitment to leveraging advanced technologies—AI, 3‑D bioprinting, and focused ultrasound—to overcome the blood‑brain‑barrier challenge and position its pipeline for eventual commercial success.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.